| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1025993541 |
| P356 | DOI | 10.1186/1546-0096-7-9 |
| P932 | PMC publication ID | 2690583 |
| P698 | PubMed publication ID | 19439078 |
| P5875 | ResearchGate publication ID | 24424312 |
| P2093 | author name string | Deborah Shapiro | |
| Kirk Sperber | |||
| Christine Hom | |||
| Julia Ash | |||
| Chun Peng Chao | |||
| P2860 | cites work | Lupus retinopathy. Patterns, associations, and prognosis | Q68518439 |
| Lupus pregnancy | Q69974752 | ||
| Hydroxychloroquine administration in pregnancy | Q71659273 | ||
| Rheumatoid arthritis | Q80560695 | ||
| Drugs for preventing malaria in pregnant women | Q24244241 | ||
| The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions | Q27860564 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Anti-inflammatory and immunosuppressive drugs and reproduction | Q28218219 | ||
| A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints | Q29614902 | ||
| Hydroxychloroquine in lupus pregnancy | Q33373145 | ||
| Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy | Q33478819 | ||
| Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases | Q33579097 | ||
| Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes | Q34180904 | ||
| Accumulation of chorio-retinotoxic drugs in the foetal eye. | Q34234023 | ||
| Antimalarial drugs in systemic lupus erythematosus: use in pregnancy | Q34458596 | ||
| Systemic lupus erythematosus. VI. Analysis of the interrelationship with pregnancy | Q34862065 | ||
| Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature | Q36049718 | ||
| Antirheumatic drugs in pregnancy and lactation | Q36272347 | ||
| Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future | Q36592626 | ||
| Ocular adverse effects associated with systemic medications : recognition and management | Q36702081 | ||
| Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction | Q36709802 | ||
| Acidification of the endocytic and exocytic pathways | Q39459758 | ||
| Surveying physicians to determine the minimal important difference: implications for sample-size calculation | Q40799596 | ||
| Antimalarial drugs in the treatment of rheumatological diseases | Q41560764 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation | Q41913288 | ||
| Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group | Q41915008 | ||
| Evidence of transplacental passage of hydroxychloroquine in humans | Q41917690 | ||
| Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. | Q41919391 | ||
| Hydroxychloroquine in pregnant patients with systemic lupus erythematosus | Q41930084 | ||
| The use of hydroxychloroquine in lupus pregnancy: the British experience. | Q41930631 | ||
| Pregnancy outcome following first trimester exposure to chloroquine | Q41942091 | ||
| THE OTOTOXICITY OF CHLOROQUINE PHOSPHATE. | Q41943335 | ||
| Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling | Q41944676 | ||
| Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases | Q43743058 | ||
| Antimalarial agents in pregnancy | Q45712596 | ||
| Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach | Q46377669 | ||
| Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort | Q47873461 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | hydroxychloroquine | Q421094 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 9 | |
| P577 | publication date | 2009-05-13 | |
| P1433 | published in | Pediatric Rheumatology Online Journal | Q15756119 |
| P1476 | title | Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases | |
| P478 | volume | 7 |
| Q38352048 | A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. |
| Q30249730 | Challenges and treatment options for rheumatoid arthritis during pregnancy. |
| Q42338695 | Editorial: Safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases |
| Q60953500 | Fetal Toxicity of Immunosuppressive Drugs in Pregnancy |
| Q54994281 | Glomerular Disease in Women. |
| Q38283472 | High-risk pregnancy and the rheumatologist. |
| Q92877815 | Host and viral mechanisms of congenital Zika syndrome |
| Q60487632 | Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease |
| Q37854742 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy |
| Q37738882 | Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases |
| Q41917416 | Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study |
| Q37821052 | Lupus and pregnancy: integrating clues from the bench and bedside |
| Q98178123 | Management of Severe COVID-19 in Pregnancy |
| Q38036105 | Management of pregnancy in systemic lupus erythematosus |
| Q28068678 | Management of rheumatoid arthritis during pregnancy: challenges and solutions |
| Q27002228 | Managing lupus patients during pregnancy |
| Q50268835 | Neonatal and Obstetrical Outcomes of Pregnancies in Systemic Lupus Erythematosus. |
| Q26998188 | Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications |
| Q37100267 | Pregnancy and autoimmune connective tissue diseases |
| Q38033398 | Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. |
| Q96612914 | Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials |
| Q35877606 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis |
| Q37943826 | Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management |
| Q43490656 | The challenge of pregnancy for patients with SLE. |
| Q38126540 | Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy |
| Q34389362 | Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know |
| Q89907294 | [Dermatological topical and systemic therapy during pregnancy] |
Search more.